SECsense Logo

BridgeBio Pharma, Inc. Form 8-K Report: Key Insights & Corporate Updates

$BBIO
Form 8-K
Filed on: 2025-01-13
Source
BridgeBio Pharma, Inc. Form 8-K Report: Key Insights & Corporate Updates

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Entity Information:
  • Company Name: BridgeBio Pharma, Inc.
  • CIK Number: 0001743881
  • Ticker Symbol: BBIO
  • State of Incorporation: Delaware (DE)
  • SEC Central Index Key: 001-38959
  • Employer Identification Number (EIN): 84-1850815
  • Address: 3160 Porter Dr. Suite 250, Palo Alto, CA 94304
  • Phone Number: 650-391-9740
  1. Filing Information:
  • Filing Type: Form 8-K
  • Filing Date: January 13, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.001 per share
  1. Reporting Period:
  • Period Start Date: January 13, 2025
  • Period End Date: January 13, 2025
  1. Additional Notes:
  • The filing does not indicate any false or misleading information, as all relevant tags in the XML structure are marked as false.

Insights:

  • The filing appears to be a current report (Form 8-K), which typically conveys unscheduled material events or corporate changes that could be of importance to shareholders.
  • The report is dated for a specific day (January 13, 2025), suggesting that it might contain time-sensitive information or an event that occurred on that date.
  • The company is listed on NASDAQ under the ticker symbol BBIO, which is relevant for investors looking into stock performance and market activity related to BridgeBio Pharma, Inc.

Conclusion:

This section of the financial report provides essential identification and context for BridgeBio Pharma, Inc., including the nature of the filing and the date, which is critical for monitoring corporate actions and compliance with SEC regulations. Investors and analysts should keep an eye on further details that may accompany this filing for a complete understanding of any material changes or events affecting the company.